A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787

Ocular Hypertension Open Angle Glaucoma

COMPLETED PHASE2

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

NCT01699464

Ocular Hypertension Open-angle Glaucoma

COMPLETED PHASE2

Ocular Hypotensive Efficacy of AR-102

NCT00523250

Glaucoma

COMPLETED PHASE2

AR-12286 in Combination With Latanoprost

NCT01302249

Glaucoma Ocular Hypertension

COMPLETED PHASE2

24-hour Efficacy of AR-12286

NCT01330979

Open Angle Glaucoma Ocular Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be randomized to receive AR-12286 Ophthalmic Solution 0.05%, 0.1%, and 0.25% or its vehicle (one eye), q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days. The first dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout this period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elevated Intraocular Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vehicle

q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.

Group Type PLACEBO_COMPARATOR

AR-12286 vehicle

Intervention Type DRUG

See arms

AR-12286 0.05%

q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.

Group Type EXPERIMENTAL

AR-12286

Intervention Type DRUG

See arms

AR-12286 0.1%

q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.

Group Type EXPERIMENTAL

AR-12286

Intervention Type DRUG

See arms

AR-12286 0.25%

q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.

Group Type EXPERIMENTAL

AR-12286

Intervention Type DRUG

See arms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AR-12286

See arms

Intervention Type DRUG

AR-12286 vehicle

See arms

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or greater.
2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). Unmedicated (post-washout, if required) IOP \>= 24 mm Hg in one or both eyes at 08:00 hours, \>= 21 mm Hg at 10:00, 12:00 and 16:00 hours on post-washout measurement (Visit 1).
3. Corrected visual acuity in each eye +1.0 logMAR (logarithm mininum angle of resolution) or better by ETDRS (Early Treatment Diabetic Retinopathy Study) in each eye (equivalent to 20/200).
4. Able and willing to give signed informed consent and follow study instructions.

Exclusion Criteria

Either eye

1. Intraocular pressure \> 36 mm Hg
2. Known hypersensitivity to any component of the formulation or to topical anesthetics, (benzalkonium chloride, etc.)
3. Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
4. History or evidence of ocular infection inflammation, or of herpes simplex keratitis, or clinically significant blepharitis or conjunctivitis at baseline (Visit 1)..
5. Contact lens wear within 30 minutes of instillation of study medication.
6. Ocular medication of any kind within 30 days of Visit 2, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 2) or c) lubricating drops for dry eye (which may be used throughout the study),
7. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (i.e., cup-disc ratio \> 0.8).
8. Central corneal thickness greater than 600 microns.
9. Any abnormality preventing reliable applanation tonometry.

Study eye:
10. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure.

Note: Previous laser peripheral iridotomy is acceptable.
11. Previous glaucoma intraocular surgery or laser procedures in study eye(s).
12. Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK (photorefractive keratectomy), LASIK (Laser-Assisted in situ Keratomileusis), etc.).

General/Systemic:
13. Clinically significant abnormalities in laboratory tests at screening (See Appendix 1).
14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
15. Participation in any investigational study within the past 30 days.
16. Changes of systemic medication during the study that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
17. Due to status of preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No